HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

KTTA — Pasithea Therapeutics Corp.

KTTA (Pasithea Therapeutics Corp.) stock: $0.47, $15.7M market cap, $45.7M cash, -$30.0M EV, $50.6M fully diluted market cap. Next expected readout: Sep-27. Lead program: PAS-004 Capsules (RAS Mutation), Phase 1. Data from Fully Diluted's biotech stocks database.

What they do

We are a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders.

Source: 10-K FY2025 via SEC EDGAR

Share price
$0.47
Market cap
$15.7M
Cash
$45.7M
Enterprise value
-$30.0M

Balance sheet

Cash$45.7M
Debt$0.0M
Net cash$45.7M
Enterprise value-$30.0M
Basic shares33.4M shares
Fully diluted shares107.7M shares
Fully diluted market cap$50.6M
Cash per share$1.37
Quarterly burn$4.7M
Cash runway9.7 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-13.

Share structure

Common
33.4M
Pre-funded warrants
54.8M
Options
7.6M
RSUs
0.0M
Warrants
11.9M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
107.7M

Cap table as of 2026-06-30.

Price history

Loading KTTA daily closes…

Loading price history…

Recently reported

PAS-004 Phase 1 Positive · 2026-11-13
PAS-004 · nf1 mutation, neurofibroma plexiform, neurofibroma, plexiform
Primary: Change in target cutaneous neurofibroma (cNF) surface area and target plexiform neurofibroma (PN) volume in the open-label Phase 1/1b Study PAS-004-103, which also assesses safety, tolerability, pharmacokinetics and pharmacodynamics — All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at the 4-12 mg doses planned for Phase 2
· cNF reductions deepened with continued treatment: median reduction in target cNF surface area reached 49% at Cycle 12, and 71% at Cycle 15 in the 4mg cohort
· All 18 evaluable participants had reductions in target PN volume; two met the REiNS partial-response threshold of at least 20%, one achieving a 22.5% reduction at the first on-treatment MRI (Cycle 4)
· At the 4, 8 and 12mg doses planned for Phase 2, 27 of 37 target cNFs (73%) were reduced by at least 25% in longest diameter, meeting the REiNS shrinkage criterion
· 19 participants enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg); 15 evaluable for cNF and 18 for PN response as of September 15, 2026
· FDA's Division of Dermatology and Dentistry cleared the IND for Study PAS-004-201, a Phase 2 trial in approximately 200 adults with NF1-associated cNF
· PAS-004 showed a terminal half-life of 40 to 60 hours, supporting once-daily dosing
Safety: No treatment-related serious adverse events, treatment-related discontinuations, retinopathy or adverse events of decreased LVEF; 97.6% of treatment-related adverse events were Grade 1 or 2, and the two Grade 3 asymptomatic CPK increases resolved following a one-week dose interruption
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego